<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02159807</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 13-0210</org_study_id>
    <nct_id>NCT02159807</nct_id>
  </id_info>
  <brief_title>Optimizing Dose of Bupivacaine in Combined Spinal Epidurals To Reduce Side Effects</brief_title>
  <official_title>Randomized Double-blinded Study Designed to Optimize the Dose of Bupivacaine in Combined Spinal Epidurals to Reduce the Incidence of Fetal Bradycardia and Maternal Hypotension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Luke's-Roosevelt Hospital Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Luke's-Roosevelt Hospital Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine what dose of medication administered through a
      combined spinal epidural (CSE) provides the optimal pain relief with the minimal amount of
      side effects. The 3 doses studied here (1.25, 1.66 and 2.5mg) are routinely use on the labor
      floor (depending on the physician preference) but the idea is to quantify safety, efficacy
      and side effects for each of these doses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A combined spinal epidural (CSE), which is the investigators' customary method of providing
      pain relief during your labor, is the identification of the epidural space in your lower back
      with a needle, followed by passing a thinner and longer needle through the first needle. This
      second needle will enter the patient's &quot;spinal&quot; (intrathecal) space by passing through the
      dura (thin covering separating the epidural space from the spinal space). The spinal
      (intrathecal) space is identified by flow of spinal fluid. The dura is the envelope around
      the spinal cord and the intrathecal space which is filled with spinal fluid. Medication will
      be injected at once into the spinal space, the thinner needle removed and a fine tube
      (catheter) will be threaded through the first needle into the epidural space. This catheter
      is in the epidural space and medication can be given through this catheter later on (hence
      the term combined) if needed. This study is a comparison of three different dosages (1.25mg,
      1.66mg and 2.5 mg) of the local anesthetic (Bupivacaine) that we frequently use in the
      spinal, mixed with 20 mcg of Fentanyl (also routinely used in standard of care practice), and
      of its effects on the patient's blood pressure (risk of maternal's drop of the blood pressure
      with possible bad effects on the blood flow to the baby), on the patient's baby's heart rate
      (risk of slowing down of the baby heart rate as a consequence of decreased blood flow to the
      baby), and the patient's pain relief (higher dose of medications are usually more effective
      for maternal pain relief but have side effects that can be bad for the mother and the baby).
      The doses of Bupivacaine the investigator routinely use on the labor and delivery floor go
      from 1.25 to 2.5 mg depending on clinician preferences. These doses are considered standard
      of care in the literature.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 24, 2015</start_date>
  <completion_date type="Actual">December 29, 2017</completion_date>
  <primary_completion_date type="Actual">December 29, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maternal Blood Pressure</measure>
    <time_frame>at 1 hour</time_frame>
    <description>Maternal diastolic blood pressure at 60 minutes after epidural to measure maternal hypotension</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fetal Heart Rate at 1 Hour</measure>
    <time_frame>at 1 hour</time_frame>
    <description>Baby's heart rate recorded with the external monitor that is placed on patient's belly, for a duration of 60 minutes after the placement of the combined spinal epidural.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Visual Analog Scale for Pain</measure>
    <time_frame>baseline and 60 minutes</time_frame>
    <description>Mean change of her pain relief from the spinal epidural 60 minutes after she received it, using a VAS, scored from 0 to 10, with higher score indicating more pain.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">170</enrollment>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>1.25 mg Bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.25mg of bupivacaine dose with 20 mcg of fentanyl was injected in the spinal portion of the anesthetic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.66 mg Bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.66mg of bupivacaine dose with 20 mcg of fentanyl was injected in the spinal portion of the anesthetic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2.5 mg Bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2.5mg of bupivacaine dose with 20 mcg of fentanyl was injected in the spinal portion of the anesthetic</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>The dose of bupivacaine administered intrathecally during placement of the spinal anesthetic.</description>
    <arm_group_label>1.25 mg Bupivacaine</arm_group_label>
    <arm_group_label>1.66 mg Bupivacaine</arm_group_label>
    <arm_group_label>2.5 mg Bupivacaine</arm_group_label>
    <other_name>Fentanyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>20 micrograms routinely administered in combination in the spinal anesthetic</description>
    <arm_group_label>1.25 mg Bupivacaine</arm_group_label>
    <arm_group_label>1.66 mg Bupivacaine</arm_group_label>
    <arm_group_label>2.5 mg Bupivacaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA (American Society of Anesthesiologists Physical status) 1-2 parturients at term
             requesting labor analgesia

          -  between 37 and 42 weeks gestational age

          -  maternal age of 18 years or greater

        Exclusion Criteria:

          -  Parturients with pre-eclampsia

          -  History of pregnancy induced hypertension

          -  Patients in whom a spinal anesthetic is contraindicated (e.g. coagulopathy, local
             infection) or those in whom a CSE cannot be performed

          -  Patients with non reassuring fetal heart rate tracings prior to placement of the CSE
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>48 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Epstein, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mount Sinai Roosevelt Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roosevelt hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>June 6, 2014</study_first_submitted>
  <study_first_submitted_qc>June 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2014</study_first_posted>
  <results_first_submitted>November 23, 2018</results_first_submitted>
  <results_first_submitted_qc>December 11, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 3, 2019</results_first_posted>
  <last_update_submitted>December 11, 2018</last_update_submitted>
  <last_update_submitted_qc>December 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pain control</keyword>
  <keyword>labor</keyword>
  <keyword>epidural</keyword>
  <keyword>pregnant</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 27, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/07/NCT02159807/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment period from April 2015 and completed Dec 2017</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>1.25 mg Bupivacaine</title>
          <description>1.25mg, mixed with 20 mcg of Fentanyl (also routinely used in standard of care practice), administered intrathecally during placement of the spinal anesthetic. Syringes will be prepared in advance by pharmacy Twenty micrograms of fentanyl is routinely administered in combination with bupivacaine in the spinal</description>
        </group>
        <group group_id="P2">
          <title>1.66 mg Bupivacaine</title>
          <description>1.66mg, mixed with 20 mcg of Fentanyl (also routinely used in standard of care practice), administered intrathecally during placement of the spinal anesthetic. Syringes will be prepared in advance by pharmacy. Twenty micrograms of fentanyl is routinely administered in combination with bupivacaine in the spinal</description>
        </group>
        <group group_id="P3">
          <title>2.5 mg Bupivacaine</title>
          <description>2.5mg, mixed with 20 mcg of Fentanyl (also routinely used in standard of care practice), administered intrathecally during placement of the spinal anesthetic. Syringes will be prepared in advance by pharmacy. Twenty micrograms of fentanyl is routinely administered in combination with bupivacaine in the spinal</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No CSF</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>elevated blood pressure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1.25 mg Bupivacaine</title>
          <description>1.25mg, mixed with 20 mcg of Fentanyl (also routinely used in standard of care practice), administered intrathecally during placement of the spinal anesthetic. Syringes will be prepared in advance by pharmacy Twenty micrograms of fentanyl is routinely administered in combination with bupivacaine in the spinal</description>
        </group>
        <group group_id="B2">
          <title>1.66 mg Bupivacaine</title>
          <description>1.66mg, mixed with 20 mcg of Fentanyl (also routinely used in standard of care practice), administered intrathecally during placement of the spinal anesthetic. Syringes will be prepared in advance by pharmacy. Twenty micrograms of fentanyl is routinely administered in combination with bupivacaine in the spinal</description>
        </group>
        <group group_id="B3">
          <title>2.5 mg Bupivacaine</title>
          <description>2.5mg, mixed with 20 mcg of Fentanyl (also routinely used in standard of care practice), administered intrathecally during placement of the spinal anesthetic. Syringes will be prepared in advance by pharmacy. Twenty micrograms of fentanyl is routinely administered in combination with bupivacaine in the spinal</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="66"/>
            <count group_id="B2" value="51"/>
            <count group_id="B3" value="48"/>
            <count group_id="B4" value="165"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="66"/>
                    <count group_id="B2" value="51"/>
                    <count group_id="B3" value="48"/>
                    <count group_id="B4" value="165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="165"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="66"/>
                    <count group_id="B2" value="51"/>
                    <count group_id="B3" value="48"/>
                    <count group_id="B4" value="165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="165"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fetal Heart Rate (FHR)</title>
          <units>beats per min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="66"/>
                    <count group_id="B2" value="51"/>
                    <count group_id="B3" value="48"/>
                    <count group_id="B4" value="165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="141.13" spread="12.34"/>
                    <measurement group_id="B2" value="136.08" spread="9.8"/>
                    <measurement group_id="B3" value="135.23" spread="9.57"/>
                    <measurement group_id="B4" value="137.48" spread="10.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pain Score</title>
          <description>Pain Visual Analog Score is from 0-10, with higher score indicating more pain</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="66"/>
                    <count group_id="B2" value="51"/>
                    <count group_id="B3" value="48"/>
                    <count group_id="B4" value="165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.15" spread="2.27"/>
                    <measurement group_id="B2" value="8.24" spread="1.61"/>
                    <measurement group_id="B3" value="8.61" spread="1.51"/>
                    <measurement group_id="B4" value="8.33" spread="1.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maternal Blood Pressure</title>
        <description>Maternal diastolic blood pressure at 60 minutes after epidural to measure maternal hypotension</description>
        <time_frame>at 1 hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1.25 mg Bupivacaine</title>
            <description>1.25mg, mixed with 20 mcg of Fentanyl (also routinely used in standard of care practice), administered intrathecally during placement of the spinal anesthetic. Syringes will be prepared in advance by pharmacy Twenty micrograms of fentanyl is routinely administered in combination with bupivacaine in the spinal</description>
          </group>
          <group group_id="O2">
            <title>1.66 mg Bupivacaine</title>
            <description>1.66mg, mixed with 20 mcg of Fentanyl (also routinely used in standard of care practice), administered intrathecally during placement of the spinal anesthetic. Syringes will be prepared in advance by pharmacy. Twenty micrograms of fentanyl is routinely administered in combination with bupivacaine in the spinal</description>
          </group>
          <group group_id="O3">
            <title>2.5 mg Bupivacaine</title>
            <description>2.5mg, mixed with 20 mcg of Fentanyl (also routinely used in standard of care practice), administered intrathecally during placement of the spinal anesthetic. Syringes will be prepared in advance by pharmacy. Twenty micrograms of fentanyl is routinely administered in combination with bupivacaine in the spinal</description>
          </group>
        </group_list>
        <measure>
          <title>Maternal Blood Pressure</title>
          <description>Maternal diastolic blood pressure at 60 minutes after epidural to measure maternal hypotension</description>
          <units>mm/Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.2" spread="8.17"/>
                    <measurement group_id="O2" value="79.58" spread="9.25"/>
                    <measurement group_id="O3" value="80.52" spread="8.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fetal Heart Rate at 1 Hour</title>
        <description>Baby's heart rate recorded with the external monitor that is placed on patient's belly, for a duration of 60 minutes after the placement of the combined spinal epidural.</description>
        <time_frame>at 1 hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1.25 mg Bupivacaine</title>
            <description>1.25mg, mixed with 20 mcg of Fentanyl (also routinely used in standard of care practice), administered intrathecally during placement of the spinal anesthetic. Syringes will be prepared in advance by pharmacy Twenty micrograms of fentanyl is routinely administered in combination with bupivacaine in the spinal</description>
          </group>
          <group group_id="O2">
            <title>1.66 mg Bupivacaine</title>
            <description>1.66mg, mixed with 20 mcg of Fentanyl (also routinely used in standard of care practice), administered intrathecally during placement of the spinal anesthetic. Syringes will be prepared in advance by pharmacy. Twenty micrograms of fentanyl is routinely administered in combination with bupivacaine in the spinal</description>
          </group>
          <group group_id="O3">
            <title>2.5 mg Bupivacaine</title>
            <description>2.5mg, mixed with 20 mcg of Fentanyl (also routinely used in standard of care practice), administered intrathecally during placement of the spinal anesthetic. Syringes will be prepared in advance by pharmacy. Twenty micrograms of fentanyl is routinely administered in combination with bupivacaine in the spinal</description>
          </group>
        </group_list>
        <measure>
          <title>Fetal Heart Rate at 1 Hour</title>
          <description>Baby's heart rate recorded with the external monitor that is placed on patient's belly, for a duration of 60 minutes after the placement of the combined spinal epidural.</description>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134.73" spread="10.87"/>
                    <measurement group_id="O2" value="137.64" spread="10.35"/>
                    <measurement group_id="O3" value="135.57" spread="10.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Visual Analog Scale for Pain</title>
        <description>Mean change of her pain relief from the spinal epidural 60 minutes after she received it, using a VAS, scored from 0 to 10, with higher score indicating more pain.</description>
        <time_frame>baseline and 60 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1.25 mg Bupivacaine</title>
            <description>1.25mg, mixed with 20 mcg of Fentanyl (also routinely used in standard of care practice), administered intrathecally during placement of the spinal anesthetic. Syringes will be prepared in advance by pharmacy Twenty micrograms of fentanyl is routinely administered in combination with bupivacaine in the spinal</description>
          </group>
          <group group_id="O2">
            <title>1.66 mg Bupivacaine</title>
            <description>1.66mg, mixed with 20 mcg of Fentanyl (also routinely used in standard of care practice), administered intrathecally during placement of the spinal anesthetic. Syringes will be prepared in advance by pharmacy. Twenty micrograms of fentanyl is routinely administered in combination with bupivacaine in the spinal</description>
          </group>
          <group group_id="O3">
            <title>2.5 mg Bupivacaine</title>
            <description>2.5mg, mixed with 20 mcg of Fentanyl (also routinely used in standard of care practice), administered intrathecally during placement of the spinal anesthetic. Syringes will be prepared in advance by pharmacy. Twenty micrograms of fentanyl is routinely administered in combination with bupivacaine in the spinal</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Visual Analog Scale for Pain</title>
          <description>Mean change of her pain relief from the spinal epidural 60 minutes after she received it, using a VAS, scored from 0 to 10, with higher score indicating more pain.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="1.13"/>
                    <measurement group_id="O2" value="0.46" spread="1.28"/>
                    <measurement group_id="O3" value="0.26" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>60 minutes</time_frame>
      <group_list>
        <group group_id="E1">
          <title>1.25 mg Bupivacaine</title>
          <description>1.25mg, mixed with 20 mcg of Fentanyl (also routinely used in standard of care practice), administered intrathecally during placement of the spinal anesthetic. Syringes will be prepared in advance by pharmacy Twenty micrograms of fentanyl is routinely administered in combination with bupivacaine in the spinal</description>
        </group>
        <group group_id="E2">
          <title>1.66 mg Bupivacaine</title>
          <description>1.66mg, mixed with 20 mcg of Fentanyl (also routinely used in standard of care practice), administered intrathecally during placement of the spinal anesthetic. Syringes will be prepared in advance by pharmacy. Twenty micrograms of fentanyl is routinely administered in combination with bupivacaine in the spinal</description>
        </group>
        <group group_id="E3">
          <title>2.5 mg Bupivacaine</title>
          <description>2.5mg, mixed with 20 mcg of Fentanyl (also routinely used in standard of care practice), administered intrathecally during placement of the spinal anesthetic. Syringes will be prepared in advance by pharmacy. Twenty micrograms of fentanyl is routinely administered in combination with bupivacaine in the spinal</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>SNOMED CT</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>vasovagal response</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Barbara Orlando</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>917-496-7490</phone>
      <email>barbara.orlando@mountsinai.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

